Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 2/20 | 0.50 |
| ▸ | SELE | P16581 | 2/20 | 0.50 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.48 |
| ▸ | SELL | P14151 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 4/20 | 0.45 |
| ▸ | PPARD | Q03181 | 4/20 | 0.45 |
| ▸ | PPARA | Q07869 | 4/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5534461 | 0.91 | SELP (0.48) | SELPSELEHPSENR1H4SELL | |
| SCHEMBL12028667 | 0.83 | SLC7A5 (0.48) | — | |
| SCHEMBL11306547 | 0.80 | HDAC11 (0.51) | SELPSELEHPSENR1H4S1PR5 | |
| SCHEMBL7339625 | 0.80 | FFAR1 (0.62) | AKR1B1S1PR5S1PR4FFAR1 | |
| SCHEMBL11935000 | 0.79 | SELP (0.49) | SELPSELEHPSENR1H4SELL | |
| SCHEMBL13370136 | 0.78 | SELP (0.56) | SELPSELEHPSENR1H4SELL | |
| SCHEMBL11073287 | 0.76 | HPSE (0.52) | SELPSELEHPSENR1H4SELL | |
| SCHEMBL3104224 | 0.76 | NR1H4 (0.56) | SELPSELEHPSENR1H4SELL | |
| SCHEMBL2468368 | 0.76 | AKR1B1 (0.57) | SELPSELEHPSENR1H4SELL | |
| SCHEMBL3273166 | 0.76 | SELP (0.55) | SELPSELEHPSENR1H4SELL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1728793-B1 | 9-SUBSTITUTED 8-OXOADENINE COMPOUND | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2016-02-03 | — | — | EP | disclosed |
| US-8969362-B2 | 9-substituted 8-oxoadenine compound | ASTRAZENECA AKTIEBOLAG (SE) | 2015-03-03 | — | — | US | disclosed |
| US-20140045837-A1 | 9-Substituted 8-Oxoadenine Compound | ASTRAZENECA AKTIEBOLAG (SE) | 2014-02-13 | — | — | US | disclosed |
| US-8575180-B2 | 9-substituted 8-oxoadenine compound | ASTRAZENECA AKTIEBOLAG (SE) | 2013-11-05 | — | — | US | disclosed |
| US-20110306610-A1 | 9-SUBSTITUTED 8-OXOADENINE COMPOUND | ASTRAZENECA AKTIEBOLAG (SE) | 2011-12-15 | — | — | US | disclosed |
| US-20070190071-A1 | 9-Substituted 8-oxoadenine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1728793-A1 | 9-SUBSTITUTED 8-OXOADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306610-A1 | 9-SUBSTITUTED 8-OXOADENINE COMPOUND | IFNAR1, IL5, IFNG | SELP 4485/4885SELE 3511/4885HPSE 3241/4885 |
| US-20070190071-A1 | 9-Substituted 8-oxoadenine compound | IFNAR1, IL5, IFNG | SELP 4485/4885SELE 3511/4885HPSE 3241/4885 |
| US-20140045837-A1 | 9-Substituted 8-Oxoadenine Compound | IFNAR1, IL5, IFNG | SELP 4409/4885SELE 3385/4885HPSE 3567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.